Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annexon Inc (NQ: ANNX )

5.390 -0.280 (-4.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 769,406
Open 5.780
Bid (Size) 5.390 (2)
Ask (Size) 5.870 (16)
Prev. Close 5.670
Today's Range 5.310 - 5.830
52wk Range 1.570 - 8.400
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
+11.36%
+11.36%
1 Month
+12.76%
+12.76%
3 Month
+13.95%
+13.95%
6 Month
-1.46%
-1.46%
1 Year
+56.23%
+56.23%

More News

Read More
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
From Annexon Biosciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
7 Top Stocks Under $10: June 2024 Edition
Via InvestorPlace
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Annexon Announces Pricing of $125 Million Underwritten Public Offering
From Annexon Biosciences
Via GlobeNewswire
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Annexon Announces Proposed Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
Via Benzinga
Gold Down 1%; Bath & Body Works Shares Tumble After Q1 Results
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
From Annexon Biosciences
Via GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.